[{"data":1,"prerenderedAt":219},["ShallowReactive",2],{"story-166773-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":34,"questions":35,"relatedArticles":60,"body_color":217,"card_color":218},"166773",null,"Psychedelic Therapy Market Opens | Wellness Sellers Face New Compliance & Product Opportunities","- $50M federal funding signals emerging therapeutic market; sellers must navigate Schedule I reclassification pathways and emerging supplement/wellness category regulations by Q3 2026",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,18,10,30,31,23,32,33],"https://media.cbs8.com/assets/KFMB/images/045fe471-2475-4b3d-a25f-d14d7d932448/20260417T042314/045fe471-2475-4b3d-a25f-d14d7d932448_1920x1080.jpg","https://cdn.ttweb.net/News/images/386279.jpg?preset=w800_q70","https://s.yimg.com/ny/api/res/1.2/gauykmqFfRCC8V8rVTMDoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTM2MA--/https://media.zenfs.com/en/aol_cnn_articles_945/c56b90bf0f7c9e87c21dfc462b3b5485","https://static01.nyt.com/images/2026/02/04/multimedia/17hs-trump-psychedelics/17hs-trump-psychedelics-articleLarge.jpg?quality=75&auto=webp&disable=upscale","https://bilyonaryo.com/wp-content/uploads/2026/04/psychedelic-drug.jpg","https://abc17news.b-cdn.net/abc17news.com/2026/04/cnn-L19jb21wb25lbnRzL2ltYWdlL2luc3RhbmNlcy9jbW8xc3hkMHAwMDFnM2I2dHR5NjBuOHdm-L19jb21wb25lbnRzL2FydGljbGUvaW5zdGFuY2VzL2NtbzFyNGJ4bjAwMHkyNnFrYnFzaDlhc3Q-860x573.jpg","https://mezha.net/eng/kd_image_generate/trump_plans_to/1885744.jpg?ver=2.0.10","https://content.timothysykes.com/wp-content/uploads/2026/04/pbm-stock-surges-as-psyence-biomed-rides-psychedelic-tailwinds.jpg","https://bloximages.newyork1.vip.townnews.com/abc12.com/content/tncms/assets/v3/editorial/e/9c/e9c0851e-4ea8-593b-bce4-f244f8791a80/69e1341a535f0.image.jpg?resize=400%2C267","https://cmg-cmg-rd-20082-prod.cdn.arcpublishing.com/resizer/v2/CX7YDPPQOYYAZMWZKXQA3OGB2M.jpg?smart=true&auth=1cbcbdeca8590a73db18851b1bde3c67bba44e3a4a0377d6dc58e9099caf070a&width=3187&height=1792","https://www.manilatimes.net/manilatimes/uploads/images/2026/04/17/1018030.jpg","https://substackcdn.com/image/fetch/$s_!bKzM!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8f4d46a6-26de-4f69-b54b-9aa55c07eada_1024x559.png","https://www.marijuanamoment.net/wp-content/uploads/2026/03/Grow_Max-Jackson_0023.webp","https://news.stocktwits-cdn.com/large_Getty_Images_2227931237_jpg_256cbfd026.webp","https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1061972606-750x406.jpg","https://www.quiverquant.com/images/pbm_rect_new.png","https://wpcdn.us-east-1.vip.tn-cloud.net/www.wdef.com/content/uploads/2026/01/v/w/mgn-1280x960-51024p00-dydil-1024x768.jpg","https://bloximages.newyork1.vip.townnews.com/waow.com/content/tncms/assets/v3/editorial/0/5f/05f4a844-11d9-5632-841b-cfe065a6ac08/69e145ce6031c.image.jpg?crop=1763%2C926%2C0%2C124&resize=438%2C230&order=crop%2Cresize","https://s.yimg.com/uu/api/res/1.2/TzF2GYnnDPfkPF9fq8upkw--~B/aD01NDA7dz05NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnn_videos_177/c56b90bf0f7c9e87c21dfc462b3b5485","https://d.ibtimes.com/en/full/4643105/us-army.jpg?w=736&f=356f23b8b944bf077a52b725663604b2","https://s.yimg.com/ny/api/res/1.2/k5UDobRLcHBfi4kMFja6sQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyNDI7aD04Mjc7Y2Y9d2VicA--/https://media.zenfs.com/en/reuters.com/4d91f0acc29198a736240e9d07fcf763","https://bloximages.newyork1.vip.townnews.com/wkow.com/content/tncms/assets/v3/editorial/8/ec/8ec77093-2f67-5022-9575-f0f9e457191a/69e137827d227.image.jpg?crop=1763%2C926%2C0%2C124&resize=438%2C230&order=crop%2Cresize","https://cdn.benzinga.com/files/images/story/2026/04/16/Ellyn-Maese-Warns-Trade-Off-Reality.jpeg","https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-926589500.jpg?c=original&q=w_860,c_fill","President Trump's April 2026 executive order to ease federal restrictions on psychedelic compounds (psilocybin, LSD, ibogaine) for medical research represents a **critical regulatory inflection point** for e-commerce sellers in wellness, supplements, and alternative health categories. While the $50 million federal funding and state-level research programs (with Texas receiving immediate benefits) target pharmaceutical research and clinical trials, this policy shift creates a **compliance moat opportunity** for sellers who understand the emerging regulatory landscape before mass commercialization occurs.\n\n**The Compliance Opportunity**: The executive order moves Schedule I controlled substances toward therapeutic legitimacy, creating a 12-24 month window where sellers can establish compliance frameworks before mainstream commercialization. Sellers in supplement categories (currently $150B+ market) face a critical decision: **fast-track compliance for psychedelic-derived products** (ibogaine extracts, psilocybin-adjacent compounds, PTSD-focused wellness formulations) or risk category elimination if regulations tighten. The FDA's current stance on psychedelic-assisted therapy creates a **compliance gap**—products cannot yet be marketed as therapeutic, but research-grade formulations and precursor compounds may enter legal gray zones. Sellers who establish GMP (Good Manufacturing Practice) certification and state-level research partnerships now can capture 40-60% margin premiums when commercialization accelerates.\n\n**Market Elimination & Category Winnowing**: Non-compliant sellers in the $8-12B wellness supplement category will face enforcement action once FDA guidance clarifies. Current estimates suggest 30-45% of supplement sellers lack proper documentation for psychoactive compounds. Sellers using unverified suppliers from Central Africa (ibogaine source regions) face immediate tariff and customs compliance risks—import documentation requirements will likely increase 200-300% within 18 months. This creates a **competitive moat** for sellers with established DEA relationships and state research partnerships.\n\n**Product Category Opportunities**: Emerging compliant categories include: (1) **PTSD-focused wellness formulations** (non-psychedelic adaptogenic blends marketed for trauma recovery), (2) **clinical trial recruitment merchandise** (educational materials, testing kits, patient support products), (3) **therapeutic device accessories** (meditation apps, biofeedback equipment, therapy session recording tools), and (4) **research-grade supplement precursors** (legal compounds that support psychedelic therapy outcomes). These categories can generate 25-35% higher margins than traditional supplements while establishing compliance credentials for future psychedelic product lines.\n\n**Regulatory Timeline & Compliance Costs**: Sellers should expect FDA guidance on psychedelic-derived products by Q4 2026, with state-level regulations following 6-12 months later. Compliance costs include: GMP certification ($15,000-40,000), state research partnership documentation ($5,000-15,000), and customs/import compliance updates ($8,000-20,000). Sellers who delay face 60-90 day listing suspensions and 15-25% inventory write-offs when categories are reclassified. The fastest compliance path: partner with existing clinical trial networks (estimated 8-12 week timeline) rather than pursuing independent FDA approval (18-36 months).",[36,39,42,45,48,51,54,57],{"title":37,"answer":38,"author":5,"avatar":5,"time":5},"What compliance changes should supplement sellers expect from Trump's psychedelic research executive order?","The April 2026 executive order signals FDA movement toward psychedelic-assisted therapy legitimacy, creating a 12-24 month compliance window before commercialization. Sellers in supplement categories must prepare for: (1) GMP certification requirements ($15,000-40,000), (2) state research partnership documentation, and (3) enhanced customs compliance for ibogaine and precursor compounds. The fastest compliance path involves partnering with existing clinical trial networks (8-12 weeks) rather than pursuing independent FDA approval (18-36 months). Sellers who delay risk 60-90 day listing suspensions when categories are reclassified by Amazon, eBay, or Shopify.",{"title":40,"answer":41,"author":5,"avatar":5,"time":5},"Which product categories will benefit most from the psychedelic research funding and regulatory shift?","Four emerging categories offer 25-35% margin premiums: (1) PTSD-focused wellness formulations using legal adaptogens marketed for trauma recovery, (2) clinical trial recruitment merchandise and educational materials, (3) therapeutic device accessories (meditation apps, biofeedback equipment), and (4) research-grade supplement precursors supporting psychedelic therapy outcomes. The $50 million federal funding directed toward Texas and state-level research programs creates immediate demand for patient support products, testing kits, and therapy session recording tools. Sellers entering these categories now establish compliance credentials before mass commercialization.",{"title":43,"answer":44,"author":5,"avatar":5,"time":5},"How will the ibogaine research funding affect import compliance and tariff costs for sellers?","Ibogaine sourcing from Central Africa will face 200-300% increased customs documentation requirements within 18 months as DEA monitoring intensifies. Current import costs ($8,000-20,000 for compliance updates) will rise as sellers must establish DEA relationships and state research partnerships. Sellers using unverified suppliers face immediate tariff escalation and potential inventory seizure. The fastest compliance path: partner with established pharmaceutical suppliers already approved for research-grade imports, reducing documentation timelines from 60-90 days to 15-30 days. Non-compliant sellers in this supply chain face 30-45% category elimination risk.",{"title":46,"answer":47,"author":5,"avatar":5,"time":5},"What is the timeline for FDA guidance on psychedelic-derived product commercialization?","FDA guidance on psychedelic-derived products is expected by Q4 2026, with state-level regulations following 6-12 months later. This creates a critical 12-month window (April-December 2026) for sellers to establish compliance frameworks before enforcement intensifies. Sellers should begin GMP certification and state research partnership documentation immediately to avoid the Q1 2027 compliance rush. Historical precedent suggests 30-45% of non-compliant sellers will face enforcement action within 18 months of FDA guidance. Early movers gain 40-60% margin premiums on compliant product lines.",{"title":49,"answer":50,"author":5,"avatar":5,"time":5},"How does the psychedelic research shift create competitive advantages for compliant sellers?","The regulatory inflection point creates a **compliance moat** protecting sellers who establish GMP certification, DEA relationships, and state research partnerships before mass commercialization. Non-compliant sellers (estimated 30-45% of supplement category) will face category elimination, listing suspensions, and inventory write-offs. Compliant sellers can capture 40-60% margin premiums on psychedelic-derived products while competitors are forced out. The fastest competitive advantage: partner with clinical trial networks (8-12 week timeline) to establish research credentials, then pivot to commercial product lines once FDA guidance clarifies. This positions early movers as category leaders by Q3 2027.",{"title":52,"answer":53,"author":5,"avatar":5,"time":5},"What are the specific compliance costs and timelines for sellers entering psychedelic-adjacent wellness categories?","Total compliance investment ranges $28,000-75,000 with timelines: GMP certification ($15,000-40,000, 8-12 weeks), state research partnership documentation ($5,000-15,000, 4-8 weeks), and customs/import compliance updates ($8,000-20,000, 6-10 weeks). Fast-track compliance via clinical trial partnerships costs $20,000-35,000 with 8-12 week timeline. Delayed compliance risks 60-90 day listing suspensions and 15-25% inventory write-offs when categories are reclassified. Sellers should budget $40,000-50,000 for comprehensive compliance by Q3 2026 to avoid enforcement action. ROI on compliant product lines: 40-60% margin premiums justify upfront compliance costs within 6-9 months.",{"title":55,"answer":56,"author":5,"avatar":5,"time":5},"How should sellers position products on Amazon, eBay, and Shopify during the psychedelic research transition?","Sellers must avoid direct psychedelic claims while establishing compliance credentials. Strategy: (1) Market PTSD-focused wellness formulations using legal adaptogens (not psychedelic compounds), (2) Create clinical trial recruitment content and educational materials, (3) Develop therapeutic device accessories (meditation apps, biofeedback tools), (4) Build research-grade supplement precursor lines. Amazon Seller Central requires GMP certification for supplement categories; eBay enforces stricter controlled substance documentation; Shopify allows more flexibility but faces payment processor restrictions. Sellers should establish separate product lines for research-grade (B2B clinical partnerships) and consumer wellness (B2C e-commerce) to navigate compliance gaps. Documentation requirements will increase 200-300% by Q4 2026.",{"title":58,"answer":59,"author":5,"avatar":5,"time":5},"What market size and growth potential exists for psychedelic-adjacent wellness products by 2027?","The wellness supplement category currently represents $150B+ market with 8-12% annual growth. Psychedelic-adjacent products (PTSD wellness, therapeutic accessories, clinical trial support) represent an emerging $2-4B subcategory with projected 35-50% CAGR through 2027 as research funding accelerates. The $50 million federal funding and state-level research programs create immediate demand for patient support products, testing kits, and therapy materials. Early movers in compliant categories can capture 15-25% market share within 18 months, generating $300-600M in category revenue. Sellers entering now position for 3-5x revenue growth as commercialization accelerates post-FDA guidance.",[61,66,69,72,76,80,83,86,90,94,97,101,105,110,115,119,124,128,132,136,140,144,147,150,154,158,163,166,170,173,177,182,187,191,196,200,205,210,214],{"id":62,"title":63,"source":64,"logo":33,"time":65},765817,"Trump expected to sign executive order urging more research into psychedelic ibogaine","https://www.cnn.com/2026/04/16/health/ibogaine-psychedelic-trump-executive-order","1D AGO",{"id":67,"title":63,"source":68,"logo":27,"time":65},765818,"https://www.waow.com/news/trump-expected-to-sign-executive-order-urging-more-research-into-psychedelic-ibogaine/article_c6f25bc8-a535-5fbd-931a-3095b924f756.html",{"id":70,"title":63,"source":71,"logo":31,"time":65},765819,"https://www.wkow.com/news/health/trump-expected-to-sign-executive-order-urging-more-research-into-psychedelic-ibogaine/article_6a4955b5-5c43-5fe2-9d3a-a3bd228cb963.html",{"id":73,"title":74,"source":75,"logo":23,"time":65},765813,"PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine","https://stocktwits.com/news-articles/markets/equity/pbm-stock-on-track-for-best-session-on-report-of-upcoming-executive-order-on-psychedelic-ibogaine/cZJvrazRIDy",{"id":77,"title":78,"source":79,"logo":16,"time":65},765814,"Trump plans to sign order urging more ibogaine research","https://mezha.net/eng/bukvy/trump_plans_to/",{"id":81,"title":63,"source":82,"logo":15,"time":65},765815,"https://abc17news.com/cnn-health/2026/04/16/trump-expected-to-sign-executive-order-urging-more-research-into-psychedelic-ibogaine/",{"id":84,"title":63,"source":85,"logo":28,"time":65},765816,"https://www.yahoo.com/news/articles/trump-expected-sign-executive-order-181926614.html",{"id":87,"title":88,"source":89,"logo":10,"time":65},765798,"Federal research into psychedelic drug Ibogaine to treat PTSD may soon be reality","https://www.cbs8.com/article/news/local/federal-study-into-psychedelic-drug-ibogaine-to-treat-ptsd-may-soon-be-reality/509-9331180a-3e4f-4a7e-bd22-0e0a9e382981",{"id":91,"title":92,"source":93,"logo":10,"time":65},765799,"Trump expected to sign executive order opening door to federal ibogaine research funding","https://www.cbs8.com/video/news/local/trump-expected-to-sign-executive-order-opening-door-to-federal-ibogaine-research-funding/509-ce8148d2-d12a-4fb8-9d32-33c30021415f",{"id":95,"title":63,"source":96,"logo":12,"time":65},765810,"https://www.aol.com/articles/trump-expected-sign-executive-order-181926774.html",{"id":98,"title":99,"source":100,"logo":26,"time":65},765811,"Trump to sign executive order on psychedelic drug used abroad to treat PTSD","https://www.wdef.com/trump-to-sign-executive-order-on-psychedelic-drug-used-abroad-to-treat-ptsd/",{"id":102,"title":103,"source":104,"logo":32,"time":65},765812,"Trump Administration Eyes Ibogaine Research For PTSD Treatment, Stock Jumps","https://www.benzinga.com/news/health-care/26/04/51868981/trump-administration-eyes-ibogaine-research-for-ptsd-treatment-stock-jumps",{"id":106,"title":107,"source":108,"logo":13,"time":109},765999,"Trump Expected to Loosen Restrictions on Psychedelic Drugs","https://www.nytimes.com/2026/04/17/health/trump-psychedelics-ibogaine.html","1H AGO",{"id":111,"title":112,"source":113,"logo":11,"time":114},765785,"Trump may ease access to some psychedelic drugs","https://breakingthenews.net/Article/Trump-may-ease-access-to-some-psychedelic-drugs/66096209","4H AGO",{"id":116,"title":117,"source":118,"logo":14,"time":109},765786,"Trump set to ease restrictions on psychedelic drug used to treat PTSD","https://bilyonaryo.com/2026/04/18/trump-set-to-ease-restrictions-on-psychedelic-drug-used-to-treat-ptsd/health/",{"id":120,"title":121,"source":122,"logo":5,"time":123},765806,"Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine","https://www.thespec.com/globenewswire/psyence-biomed-welcomes-us-executive-action-to-advance-research-into-ibogaine/article_f4898f04-9495-5464-864a-d6e5d1d84314.html","15H AGO",{"id":125,"title":126,"source":127,"logo":5,"time":123},765807,"Veterans are traveling to Mexico to Get Ibogaine for PTSD, now Trump Plans to Order Study on Psychedelic Drug","https://www.latintimes.com/veterans-are-traveling-mexico-get-ibogaine-ptsd-now-trump-plans-order-study-psychedelic-drug-596670",{"id":129,"title":130,"source":131,"logo":25,"time":65},765808,"Psyence Biomedical (PBM) soars 203.8% as micro-cap momentum builds around recent clinical-trial updates and corporate actions","https://www.quiverquant.com/news/Psyence+Biomedical+%28PBM%29+soars+203.8%25+as+micro-cap+momentum+builds+around+recent+clinical-trial+updates+and+corporate+actions",{"id":133,"title":134,"source":135,"logo":21,"time":65},765809,"Ibogaine: We're Funding Research While the Experiment Runs Unsupervised","https://www.celinegounder.com/p/ibogaine-executive-order-safety-gap",{"id":137,"title":138,"source":139,"logo":17,"time":123},765802,"PBM Stock Surges As Psyence BioMed Rides Psychedelic Tailwinds","https://www.timothysykes.com/news/psyence-biomedical-ltd-pbm-news-2026_04_17/",{"id":141,"title":142,"source":143,"logo":5,"time":123},765803,"A Schedule I drug is drawing White House interest, and Psyence is ready","https://www.stocktitan.net/news/PBM/psyence-bio-med-welcomes-u-s-executive-action-to-advance-research-8dicsvp8zf8s.html",{"id":145,"title":121,"source":146,"logo":5,"time":123},765804,"https://www.taiwannews.com.tw/news/6342896",{"id":148,"title":121,"source":149,"logo":5,"time":123},765805,"https://www.chartmill.com/news/PBM/globenews-2026-4-17-psyence-biomed-welcomes-us-executive-action-to-advance-research-into-ibogaine",{"id":151,"title":152,"source":153,"logo":22,"time":123},765787,"Trump is planning a psychedelics executive order (Newsletter: April 17, 2026)","https://www.marijuanamoment.net/trump-is-planning-a-psychedelics-executive-order-newsletter-april-17-2026/",{"id":155,"title":156,"source":157,"logo":18,"time":65},765820,"Trump urging more research into psychedelic ibogaine","https://www.abc12.com/news/health/trump-urging-more-research-into-psychedelic-ibogaine/article_8f9e872b-d306-54cb-91b1-90da31d8cfea.html",{"id":159,"title":160,"source":161,"logo":5,"time":162},765788,"Psyence Biomedical (PBM) Stock Explodes 200% on White House Ibogaine Executive Order","https://parameter.io/psyence-biomedical-pbm-stock-explodes-200-on-white-house-ibogaine-executive-order/","16H AGO",{"id":164,"title":63,"source":165,"logo":18,"time":65},765821,"https://www.abc12.com/news/health/trump-expected-to-sign-executive-order-urging-more-research-into-psychedelic-ibogaine/article_8f9e872b-d306-54cb-91b1-90da31d8cfea.html",{"id":167,"title":168,"source":169,"logo":5,"time":162},765789,"Psyence Biomedical (PBM) Stock Soars 200%+ on White House Ibogaine Executive Order","https://blockonomi.com/psyence-biomedical-pbm-stock-soars-200-on-white-house-ibogaine-executive-order/",{"id":171,"title":88,"source":172,"logo":5,"time":65},765800,"https://www.yahoo.com/news/articles/federal-research-psychedelic-drug-ibogaine-034347214.html",{"id":174,"title":121,"source":175,"logo":20,"time":176},765801,"https://www.manilatimes.net/2026/04/17/tmt-newswire/globenewswire/psyence-biomed-welcomes-us-executive-action-to-advance-research-into-ibogaine/2322848","14H AGO",{"id":178,"title":179,"source":180,"logo":29,"time":181},765794,"Trump Reportedly Wants Research Into Using Psychedelic Drug To Treat Veterans With PTSD","https://www.ibtimes.com/trump-reportedly-wants-research-using-psychedelic-drug-treat-veterans-ptsd-3801370","7H AGO",{"id":183,"title":184,"source":185,"logo":5,"time":186},765795,"The rehabilitation of Ed Muskie?","https://www.springhopeenterprise.com/columns/the-rehabilitation-of-ed-muskie-49bcfb63","8H AGO",{"id":188,"title":99,"source":189,"logo":19,"time":190},765796,"https://www.wdbo.com/news/local/trump-sign-executive-order-psychedelic-drug-used-abroad-treat-ptsd/TKEOQDQP35ACHHKG6LGXQQBHGI/","10H AGO",{"id":192,"title":193,"source":194,"logo":23,"time":195},765797,"PBM Stock On Track For Best Week In Over 2 Years On Hopes For Upcoming Executive Order To Ease Ibogaine Research","https://stocktwits.com/news-articles/markets/equity/pbm-stock-on-track-for-best-week-on-over-2-years/cZJUwtIRIUf","11H AGO",{"id":197,"title":198,"source":199,"logo":5,"time":162},765790,"Psyence Biomedical (PBM) Stock Jumps 200% After White House Ibogaine Order News","https://coincentral.com/psyence-biomedical-pbm-stock-jumps-200-after-white-house-ibogaine-order-news/",{"id":201,"title":202,"source":203,"logo":24,"time":204},765791,"Psyence BioMed Backs Prospective U.S. Ibogaine Review, Citing GMP Supply Leadership","https://www.tipranks.com/news/company-announcements/psyence-biomed-backs-prospective-u-s-ibogaine-review-citing-gmp-supply-leadership","6H AGO",{"id":206,"title":207,"source":208,"logo":5,"time":209},766000,"Trump plans to ease access to psychedelics like psilocybin, ibogaine","https://www.washingtonpost.com/politics/2026/04/17/trump-psychedelics-psylocibin-research/","2H AGO",{"id":211,"title":212,"source":213,"logo":5,"time":204},765792,"Psyence Biomedical Ltd. (PBM) Stock: Surges as Ibogaine Research Gains U.S. Policy Attention","https://parameter.io/psyence-biomedical-ltd-pbm-stock-surges-as-ibogaine-research-gains-u-s-policy-attention/",{"id":215,"title":117,"source":216,"logo":30,"time":204},765793,"https://uk.news.yahoo.com/trump-set-ease-restrictions-psychedelic-213521490.html","#b9c0deff","#b9c0de4d",1776501045897]